LENSAR Inc (LNSR) News

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENSAR Reports First Quarter 2024 Results and Provides Business Update

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for...

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...